Steven Leonard Chapman Sells 4,523 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 4,523 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $130.40, for a total transaction of $589,799.20. Following the completion of the transaction, the chief executive officer now directly owns 191,163 shares in the company, valued at $24,927,655.20. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, September 16th, Steven Leonard Chapman sold 5,024 shares of Natera stock. The shares were sold at an average price of $128.48, for a total value of $645,483.52.
• On Thursday, August 15th, Steven Leonard Chapman sold 5,583 shares of Natera stock. The stock was sold at an average price of $118.91, for a total value of $663,874.53.
• On Monday, July 29th, Steven Leonard Chapman sold 4,084 shares of Natera stock. The stock was sold at an average price of $102.77, for a total value of $419,712.68.
• On Monday, July 22nd, Steven Leonard Chapman sold 2,638 shares of Natera stock. The shares were sold at an average price of $105.16, for a total transaction of $277,412.08.

Natera Stock Performance

Shares of NTRA stock opened at $122.40 on Friday. The firm has a 50 day moving average of $123.30 and a two-hundred day moving average of $110.36. The stock has a market capitalization of $15.03 billion, a PE ratio of -39.23 and a beta of 1.53. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34. Natera, Inc. has a 52 week low of $36.90 and a 52 week high of $133.54.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The firm had revenue of $413.35 million during the quarter, compared to analyst estimates of $343.00 million. During the same period last year, the business posted ($0.97) earnings per share. Natera’s revenue was up 58.1% compared to the same quarter last year. On average, research analysts predict that Natera, Inc. will post -1.96 EPS for the current fiscal year.

Institutional Trading of Natera

Large investors have recently made changes to their positions in the company. Quent Capital LLC grew its holdings in Natera by 3.2% during the 1st quarter. Quent Capital LLC now owns 3,205 shares of the medical research company’s stock worth $293,000 after acquiring an additional 99 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Natera by 32.7% in the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 106 shares in the last quarter. Moss Adams Wealth Advisors LLC lifted its position in shares of Natera by 5.4% during the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 2,646 shares of the medical research company’s stock worth $336,000 after purchasing an additional 135 shares during the last quarter. Quarry LP grew its stake in shares of Natera by 148.4% during the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after purchasing an additional 190 shares in the last quarter. Finally, Itau Unibanco Holding S.A. purchased a new position in Natera in the second quarter valued at $28,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

NTRA has been the subject of several recent analyst reports. BTIG Research raised their price objective on shares of Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Canaccord Genuity Group lifted their price target on shares of Natera from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, August 27th. Morgan Stanley upped their price objective on Natera from $125.00 to $132.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. StockNews.com upgraded Natera from a “sell” rating to a “hold” rating in a research report on Thursday. Finally, Stephens reiterated an “overweight” rating and set a $125.00 price target on shares of Natera in a report on Friday, August 9th. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $124.44.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.